Company intelligence / Profile preview

LIPAC Oncology

Ownership: Private
Development stage: Phase 2

Overview

Completed Phase 1-2a clinical trial for LiPax that demonstrated safety and tolerability, with projected two-year 83% recurrence-free survival rates in patients with low-grade highly recurrent NMIBC versus 49% for current treatments[2]

Therapeutic areas: Oncology
Modalities: Liposomal DrugSmall molecule drug
Industry: Biotech

Drug pipeline

1 asset

TBC-1002

Unknown

Partnerships

Huons Co. Ltd.

Beyond the preview

Go deeper on LIPAC Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIPAC Oncology.

Explore the full profile